The invited review covers different research areas of silver nanoparticles (AgNPs), including the synthesis strategies of AgNPs, antimicrobial and anti-inflammatory properties of AgNPs, osteoconductive and osteoinductive activities of AgNP-based materials, and potential toxicity of AgNPs. The potential mechanisms of AgNP’s biological efficacy as well as its potential toxicity are discussed as well. In addition, the current development of AgNP applications, especially in the area of therapeutics, is also summarized.
1. Introduction
Silver has been used as an antimicrobial agent for centuries. For example, the Phoenicians used silver vessels to preserve water and wine during their long voyages [1]. In addition, ancient Egyptians believed that silver powder provided beneficial healing and antidisease properties; thus silver compounds were used for prohibiting wound infection prior to antibiotics [1]. In 1884, German obstetrician Crede introduced 1% silver nitrate (AgNO3) as an eye solution for prevention of gonococcal ophthalmia neonatorum, which is most likely the first scientifically documented medical use of silver [1]. In modern society, topically used silver sulfadiazine cream is the standard antibacterial treatment for serious burn wounds and is still widely used in burn units today [2]. However, inadequate local retention and severe cytotoxic effects limited the clinical use of these ionic reservoir forms of silver materials [3–5].
Due to recent advances in nanotechnology, it is now possible to produce silver at the nanoscale [6, 7]. In addition to their potential electronic and transparent conductor applications, the emergence of nanosilver materials in antimicrobial consumer goods and medical products is driving the growth of the nanosilver market, which is expected to grow in value from US$290 million in 2011 to around US$1.2 billion by 2016 (http://www.merid.org/Content/News_Services/Nanotechnology_and_Development_News/Articles/2011/Sep/14/nanosilver.aspx). Among the different nanosilver preparations, silver nanoparticles (AgNPs) are made up of 20–15,000 silver atoms, generally range from 1 to 100 nm in diameter and present in one dimension [8]. These extremely small dimensions lead to a high surface area to volume ratio and, subsequently, change the physical, chemical, and biological properties of AgNPs [9, 10]. This review critically outlines recent developments in the synthesis, physicochemical properties, toxicity, and biomedical applications of AgNPs.
2. Synthesis of AgNPs
AgNPs can be synthesized in a variety of different ways, each with its own advantages and disadvantages. Till now, the most common methods of AgNPs synthesis are through chemical reduction of silver salt (e.g., AgNO3) using a reducing agent (e.g., sodium borohydride) [11]. During chemical reduction, silver ion (Ag+) receives an electron from the reducing agent and reverts to its metallic form (Ag0) eventually clustering to form AgNPs. AgNO3 is the most often used silver salt for these chemical methods of AgNP synthesis due to its low cost and high stability [10]. Generally, a capping agent [e.g., poly(N-vinyl-2pyrrolidone) (PVP)] is used during chemical reduction to stabilize the nanoparticles and prevent them from aggregating [11]. However, reducing agents and organic solvents used in chemical reduction, such as N,N-dimethylformamide, hydration hydrazine, and sodium borohydride, are highly reactive and pose potential environmental and biological risks [12]. Moreover, the inability to control the size of the AgNPs obtained by chemical reduction could result in a wide distribution of sizes of AgNPs obtained.
Photoreduction of silver salt in the presence of PVP or citrate by ultraviolet (UV) light is another simple and effective strategy to produce AgNPs [11, 13, 14]. However, most photoreduction methods still use organic solvents, such as PVP, and are unable to control the size of obtained AgNPs [11, 13, 14].
Recent efforts have been focused on developing new green chemistry methods of AgNPs synthesis with the advantage of using natural products and avoiding toxic reducing agents, organic solvents, and wasteful purifications with high cytotoxic residuals. With these methods, molecules produced by living organisms such as bacteria, fungi, or plants replace the reducing and capping agents [15–18]. For example, AgNO3 is added to chitosan obtained from various species of bacteria and dissolved in acetic acid. The silver ions are then reduced through gamma radiation and stabilized by chitosan [19, 20]. There have also been efforts to synthesize AgNPs in the lamellar space of montmorillonite/chitosan by utilizing the UV irradiation reduction method in the absence of any reducing agent or heat treatment [21]. Additionally, AgNPs have been synthesized via photoreduction of AgNO3 in layered inorganic clay suspensions, laponite, which serve as stabilizing agents that prevent nanoparticles from aggregating instead of using PVP [22]. The disadvantage to using these types of green synthesis is the potential of contamination due to the pathogenic bacteria created during the purification [10]. Consequently, herbal extracts and essential oils are gaining in popularity for methods of green synthesis due to their antioxidant and antimicrobial properties while avoiding the use of pathogenic bacteria [23–25]. However, the disadvantage of using herbal extracts is once again the wide distribution of particle sizes obtained.
In addition, there have also been novel developments by using green physical methods for AgNP synthesis avoiding the use of chemicals completely. One such method, laser ablation, can synthesize pure colloidal AgNPs in solutions without the use of chemical reagents [27, 28]. However, the concentration and morphology of these AgNPs are inconsistent since they are dependent on many parameters such as number of laser shots, wavelength of the laser, laser fluence, liquid medium, and ablation time duration [27, 28]. Another chemical-free method for AgNP synthesis involves the application of an electrical current between two silver wires in deionized water causing surface silver atoms to evaporate and condense back into aqueous AgNPs [29]. Without the use of chemicals, there are no toxic residuals or contaminations. However, since no capping agents are used, agglomeration of AgNPs may pose a problem [30]. To date, perhaps the most effective method for AgNP synthesis is the production through a novel, nonchemically based proprietary process (USPTO 7,282,167). In this process, silver granules with a purity of 99.99% are distilled into silver vapor by heating on a ceramic conductive element. By controlling the generation rate of silver vapor, gas flow, and reactor pressure, the nucleation rate of silver nanoclusters can be designed to produce nanosilver liquid droplets, which are then condensed in a stream of flowing helium gas into solid crystalline spherical AgNPs of desired size. The hot nanoparticles are then attracted to a cooled chamber wall by thermophoresis where they are mechanically collected and packaged for use. Furthermore, the active surface of the obtained highly purified (>99.9% pure) 20–40 nm AgNPs (15–25 m2/g) is much greater compared to commercial nonnanoscale silver powder (1-2 m2/g) and previously reported AgNPs (4 m2/g) [31, 32].
3. Biological Properties of AgNPs
Currently, the unique antimicrobial properties of AgNPs have led to their application in areas such as clothing manufacturing, food preservation, and water purification [33–36]. More importantly, AgNPs are being increasingly utilized in the medical industry due to their antibacterial, antifungal, antiviral, anti-inflammatory, and osteoinductive effects as well as their ability to enhance wound healing [32, 37–42].
3.1. Antibacterial Properties of AgNPs
Antibiotics are standard antimicrobials used in medicine that bind to specific chemical targets of bacteria not present in humans [41]. However, this binding specificity narrows the number of bacterial species that are vulnerable to a specific antibiotic and contributes to the antibiotic resistance developed by bacteria, ultimately creating multidrug resistant bacteria [43]. With the increasing number of infections due to multidrug resistant bacteria, there has been a need for effective antimicrobial alternatives. Thus, silver is a great alternative because it is an antiseptic that targets a broad spectrum of Gram+ and Gram− bacteria as well as vancomycin-resistant strains [7, 31, 36, 40, 43]. Moreover, silver-resistant bacteria are rarely observed in hospital microbial germ flora because silver resistance requires one generation of bacteria to undergo three separate mutations in three different bacterial systems [31, 44].
Mechanistically, silver-based materials are thought to release silver ions (Ag+) in aqueous solution, which account for their antibacterial properties by attaching to specific thiol (–SH) groups containing sulfur and hydrogen found in a variety of structural and functional bacterial proteins [45–47]. It should be noted that the reservoir form of the active silver ions might differ [43]. For instance, the reservoir form of AgNO3 is a chemical combination of Ag(I) and nitrate, but AgNO3 is not suitable for sustained local application due to its high solubility as an ionic salt. Nonnanoscale elemental silver [Ag(0)] used in silverware and jewelry is relatively insoluble in most fluids, resulting in minimal oxidative Ag+ release [43]. Thus, neither the in vitro antibacterial action nor the clinical behavior of nonnanoscale silver-coated stainless steel cortical screws significantly differed from that of the uncoated ones [48]. Due to the greater surface-to-mass ratio, AgNPs offer greater active surface, higher solubility, and chemical reactivity. As a result, although the reservoir form for AgNPs is also elemental silver [Ag(0)], AgNPs have higher release of oxidative Ag+ and/or partially oxidized AgNP with chemisorbed (surface-bound) Ag(I) and thus have higher antibacterial activity compared with conventional silver reparations [40, 49, 50].
However, a comparative study of AgNPs, AgNO3, and silver chloride (AgCl) found that AgNPs have higher antibacterial properties than free silver ions (Ag+) [51]. This implies that AgNPs have intrinsic antibacterial properties not dependent on the release of silver ions (Ag+). One possible mechanism of Ag+ releasing-independent bactericidal effects of AgNPs is partly due to the ability of AgNPs to attach to the bacterial cell wall and penetrate it, thereby increasing its permeability and, ultimately, leading to cell death [52]. Another possible mechanism attempts to explain the antibacterial effect of positively charged silver atoms (Ag+) on the surface of AgNPs through the formation of free radicals and the subsequent free radical-induced membrane damage [53]. Furthermore, a recent study suggests a novel mechanism for the antibacterial effect of AgNPs, namely, the induction of a bacterial apoptosis-like response [54]. This new proposed mechanism involves an accumulation of reactive oxygen species (ROS), increased intracellular calcium levels, and phosphatidylserine exposure in the outer membrane, all hallmarks of early apoptosis. It also includes disruption of the membrane potential and DNA degradation, indicators of late apoptosis, in bacterial cells treated with AgNPs [54]. Collectively, it is believed that AgNPs are thought to interact with the bacterial DNA, the peptidoglycan cell wall and plasma membrane, and the bacterial proteins involved with the electron transport chain to produce their bactericidal effects [30, 47, 55–57]. Although it is not fully understood which mechanism provides the main antibacterial effect, a combined effect of each mechanism provides broad-spectrum antibacterial resistance.
It is worth noting that the size and shape of nanosilver influence its antibacterial efficacy. Previous studies have demonstrated that 5–50 nm sized AgNPs are bactericidal [31]. Further investigation suggested that the greater the surface area of AgNPs is, the greater the antibacterial activity is [58–60]. In addition, Sadeghi et al. reported that nanoscale silver plates demonstrated the best antimicrobial activity against Staphylococcus aureus and Escherichia coli compared with nanosca le silver rods and particles [61]. Antibacterial activity of nanosilver was found to be dependent on the surface area of nanosilver shapes with nanoscale silver plates showing the greatest surface area [61]. Thus, nanosilver with the greatest surface area exhibits better antibacterial properties at lower concentrations [61].
As discussed, the evidence supporting AgNPs as an effective antimicrobial agent is abundant with AgNPs showing broad-spectrum resistance to bacterial strains such as S. aureus (including methicillin resistant strains, known as MRSA), Staphylococcus epidermidis (including methicillin resistant strains, known as MRSE), Enterococcus faecalis, Enterococcus faecium, E. coli, Pseudomonas aeruginosa, and Klebsiella pneumonia and even vancomycin-resistant strains [7, 31, 32, 36, 40, 42, 43].
3.2. Antifungal Properties of AgNPs
Long-term, repetitive administration of standard antifungal drugs leads to increased fungal resistance, especially by the Candida species [39]. Therefore, new antifungal agents are constantly being investigated. AgNPs have displayed many antifungal properties against common fungi and thus offer potential as an effective antifungal agent. A recent study found that a AgNP-coated reverse osmosis membrane, which is used in water purification systems, exhibited good antifungal activities against fungal strains such as Candida tropicalis, Candida krusei, Candida glabrata, and Candida albicans [36]. Additionally, Pulit et al. reported that AgNP suspensions created from aqueous raspberry extract acted as effective growth inhibition factors against two resistant fungal strains Cladosporium cladosporioides and Aspergillus niger [39]. Furthermore, a higher concentration of AgNPs induced stronger reduction of fungal growth in both cases. With the promising potential of AgNPs as a broad-spectrum antifungal agent, further investigation is warranted to elucidate the mechanisms concerning their antifungal properties.
3.3. Antiviral Properties of AgNPs
Various viruses, such as influenza, hepatitis, herpes simplex virus (HSV), and human immunodeficiency virus (HIV), can be life threatening [62]. Although many vaccines have been developed against various viruses, medicine has yet to develop a broad-spectrum antiviral vaccine. Furthermore, these viruses are developing antiviral resistance to current treatments and classical antiviral drugs, especially in immunocompromised patients [62]. In light of this, there is a pressing need for the development of new antiviral agents against a broad spectrum of viruses. AgNPs act as a broad-spectrum agent against a variety of viral strains and are not prone to developing resistance [10]. For example, studies have demonstrated antiviral activity of AgNPs against HSV-1, HSV-2, hepatitis B, and human immunodeficiency virus 1 (HIV-1) [63–66]. With regard to HSV-1, AgNPs are hypothesized to target the virus and to compete for its binding to cellular heparin sulfate through their sulfonate end groups, leading to the blockage of viral entry into the cell and the prevention of subsequent infection [63]. Additionally, a recent study demonstrated that 100 μg/mL of AgNPs could completely inhibit HSV-2 replication [66]. AgNPs at nontoxic concentrations were capable of inhibiting HSV-2 replication when administered prior to viral infection or soon after initial virus exposure. These findings suggest that the mode of action of AgNPs occurs during the early phases of viral replication [66]. Furthermore, there has been evidence of AgNP’s antiviral activity against HIV-1 at noncytotoxic concentrations. AgNPs exerted anti-HIV activity at an early stage of viral replication, most likely as a virucidal agent or as an inhibitor of viral entry [65].
3.4. Anti-Inflammatory Properties of AgNPs
Despite the billions of dollars that have been spent on immunological research, few effective anti-inflammatory drugs have emerged [72]. Thus, an urgent need for new drugs exists, as many inflammatory diseases are insufficiently responsive to current medications [72]. Recently, there has been increasing evidence that AgNPs are viable anti-inflammatory agents. Initially, anti-inflammatory properties of AgNPs were investigated by applying AgNP-coated, 0.5% silver nitrate (AgNO3), or saline wound dressings to a porcine model of contact dermatitis [37]. AgNP-coated wound dressings outperformed other wound dressings as erythema, edema, and histological data showed that AgNP-treated pigs had near-normal skin after 72 hours, while other treatment groups remained inflamed [37]. Furthermore, AgNP-coated wound dressings decreased levels of proinflammatory cytokines transforming growth factor- (TGF-) β and tumor necrosis factor- (TNF-) α compared with other treatment groups. Similarly, another study evaluating the anti-inflammatory effects of AgNPs on an allergic rhinitis mouse model reported reduced nasal symptoms in sensitized mice and an inhibition of ovalbumin-specific immunoglobulin E, interleukin- (IL-) 4, and IL-10 [73]. Moreover, decreased inflammatory cell infiltration and goblet cell hyperplasia were also observed [73]. Further evidence of the anti-inflammatory effects of AgNPs has been demonstrated in a postoperative peritoneal adhesion model and through the use of AgNP-coated sutures [74, 75]. Wong et al. found that AgNPs are effective at decreasing inflammation in peritoneal adhesions without significant cytotoxic effects while Zhang et al. reported that using AgNP-coated sutures decreased inflammation and improved mechanical strength at intestinal anastomosis in mice [74, 75]. Our previous studies have also demonstrated that AgNP/poly(lactic-co-glycolic acid) (PLGA-) coated stainless steel alloy (SNPSA) materials significantly reduced bacterial infection and inflammatory cell infiltration in the intramedullary tissue in rat femoral canals (Figure 1) [76]. Mechanistically, the anti-inflammatory effects of AgNPs are not fully understood but are thought to be associated with the TNF-α pathway [74].
Histological and immunohistochemical staining of contaminated 0% and 2% AgNP/PLGA-coated 316L stainless steel alloy (SNPSA) implants in rat femoral canals (FCs) at 8 weeks after implantation. 103 colony forming units (CFU) S. aureus Mu50 or P. aeruginosa PAO-1 in 10 μL phosphate buffered saline (PBS) (105 CFU/mL, the typical criteria for invasive tissue infection [26]) were pipetted into the canal before implantation for bacterial invasion. Taylor-modified Brown and Brenn Gram staining (a) and Giemsa staining (b) revealed bacterial persistence (yellow dotted circles) with massive inflammatory cell infiltration (red arrowheads) in the intramedullary tissue around 0% SNPSA implants in rat FCs. In contrast, no bacterial survival was evident around 2% SNPSA implants in the same situation, and inflammatory cell infiltration in the intramedullary tissues around the implants was minimal. Moreover, only minimal bone formation around the 0% SNPSA groups was observed, whereas significant bone formation (blue arrows) was detected around 2% SNPSA implants, as shown by hematoxylin and eosin (H&E) staining (c), Masson’s trichrome staining (d), and immunohistochemical staining of high-intensity osteocalcin signals (e). Yellow scale bar = 50 μm; red scale bar = 100 μm; white scale bar = 500 μm; black scale bar = 200 μm. Reprinted from Biomaterials, Vol. 33, Y. Liu and Z. Zheng et al., “The antimicrobial and osteoinductive properties of silver nanoparticle/poly (DL-lactic-co-glycolic acid)-coated stainless steel,” pp. 8745–8756, 2012, with permission from Elsevier.
3.5. Osteoconductivity and Osteoinductivity of AgNP-Based Materials
Previously, by implanting AgNP/PLGA composite grafts for the healing of infected bone defects into grossly infected critical-sized bone segmental defects, we demonstrated that AgNP/PLGA composite grafts possess significant, antibacterial properties and osteoconductivity in vivo (Figure 2) [32]. AgNP/PLGA composite grafts displayed osteoconductive properties as they did not inhibit adherence, proliferation, alkaline phosphatase activity, or mineralization of ongrowth MC3T3-E1 preosteoblasts in vivo [32]. In a follow-up experiment, we unexpectedly found that SNPSA materials not only exhibited strong antibacterial activity in vitro and ex vivo, but also promoted MC3T3-E1 preosteoblast proliferation and maturation in vitro [42]. Furthermore, SNPSA implants induced osteogenesis while suppressing bacterial survival in contaminated rat femoral canals with no observed cytotoxicity (Figure 1) [42]. These findings require more research into the osteoconductive and osteoinductive properties of AgNP-based materials, but they offer promising therapeutic material for orthopedic surgery.
Histological and immunohistochemical staining of contaminated rat femoral segmental (FSD) defects implanted with 0.0%, 1.0%, and 2.0% AgNP/PLGA bone grafts coupled with 30 μg/mL bone morphogenetic protein 2 (BMP-2) at 12 weeks after implantation. With a small oscillating saw blade, a 6 mm critical-sized middiaphyseal defect was created in 16–18-week-old male SD rat femur. The volume of the defect was approximately 75 μL. 108 CFU S. aureus Mu50 in 75 μL 20% gelatin gel was implanted into the defect before implantation. H&E staining and Masson’s trichrome staining (a) revealed no bone regeneration in BMP-2/0.0% AgNP/PLGA (control BMP-2 coupled control PLGA) implanted groups with obvious continued bacterial contamination evidenced by Taylor modified Brown and Brenn Gram stain (red arrows). However, BMP-2/2.0% NS/PLGA grafts promoted significantly greater bone formation to form a mineralized bony bridge between the two defect ends by eliminating bacteria in the defect area (a). Immunohistochemical staining against osteocalcin showed active bone regeneration around the mineralized bridge and in the marrow-like cavities in the bridge (b). Black scale bar = 2 mm; green scale bar =100 μm; red scale bar = 10 μm. Reprinted from Biomaterials, Vol. 31, Z. Zheng et al. “The use of BMP-2 coupled—nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects,” pp. 9293–9300, 2010, with permission from Elsevier.
4. Toxicity of AgNPs
Applying silver as an antimicrobial agent has been hindered by its potential toxic effects, such as argyria, an irreversible pigmentation of the skin and eyes due to inappropriate silver deposition [3]. Thus, the toxicity of AgNPs must be investigated for commercial products and before widespread medical application. Also, environmental pollution must be considered to avoid ecological damage.
AgNPs enter the human body most often through the respiratory tract, gastrointestinal tract, skin, and female genital tract, as well as through systemic administration [77]. Recently, an in vivo oral toxicity study of AgNPs on Sprague-Dawley (SD) rats demonstrated the accumulation of AgNPs in the blood, liver, lungs, kidneys, stomach, testes, and brain, but showed no significant genotoxicity function after oral administration of AgNPs of 60 nm average size for 28 days at different doses [78]. Similarly, another in vivo 28-dayinhalation toxicity study of 1.98–64.9 nm AgNPs on SD rats found no effects on respiratory function, hematology, or blood biochemical values [79]. In our previous studies, 3D porous graft and 43 μm thick PLGA coating composited by up to 2% 20–40 nm AgNPs and PLGA materials did not show significant cytotoxicity against preosteoblast MC3T3-C1 cells in vitro or toxicity during 8-week bone regeneration in SD rats in vivo [32, 42]. Other studies have shown that 20–25 nm AgNPs effectively inhibit microorganisms without causing significant cytotoxicity and that 10–20 nm AgNPs are nontoxic in mice and guinea pigs when administered by the oral, ocular, and dermal routes [32, 80]. In contrast, a 90-day whole body inhalation toxicity study of 18 nm AgNPs on SD rats reported that prolonged exposure to AgNPs elicited an inflammatory response within the alveoli and induced alterations in lung function at all particle concentrations [81]. Also, AgNPs have been reported to cross the blood-brain barrier in rats and induce neuronal degeneration and necrosis through accumulation in the brain over a long period of time [82]. Additionally, Vandebriel et al. and de Jong et al. found that intravenous administration of both 20 and 100 nm AgNPs in a 28-day repeated-dose toxicity study in SD rats induces suppression of the functional immune system [83, 84]. In the area of development, a study reported that AgNPs less than 12 nm in size affected early development of fish embryos, caused chromosomal aberrations and DNA damage, and induced proliferation arrest in cell lines of zebrafish indicating that AgNPs must be investigated for their potential teratogenic effects in humans [85]. In vitro studies have demonstrated that AgNPs are cytotoxic to various types of cells including neuroendocrine cells, mouse germ line cells, mouse fibroblasts, rat liver cells, human alveolar epithelial cell line, human peripheral blood mononuclear cells, normal human lung fibroblast cells, and human glioblastoma cells [86–91]. These conflicting results reveal the difficulty of pinpointing the overall toxicity of AgNPs to humans because the tremendous variation in particle size, particle aggregation, and concentration or coating thickness (in implants) of AgNPs has different profiles of silver release and bioactivity [43]. In short, much longer and detailed studies must be carried out to seriously consider AgNPs’ potential toxicity in humans.
A potential contributing factor to AgNPs cytotoxicity is the oxidative stress caused by the creation of reactive oxygen species after AgNPs enter the cell [89]. AgNPs also damage cellular components leading to DNA damage, activation of antioxidant enzymes, depletion of antioxidant molecules (e.g., glutathione), binding and disabling of proteins, and damage to the cell membrane [92]. However, an emerging study suggests that cellular oxidative stress may not be the main cause of toxicity and that it might be a different mechanism all together. Two widely used in vitro human cell lines for determining cytotoxicity in the liver and gastrointestinal tract, hepatoblastoma HepG2 and colon carcinoma Caco2, did not display any AgNP-induced oxidative stress when exposed to AgNPs at a concentration of 1–20 μg/mL [93]. These results suggest that cellular oxidative stress did not play a major role in the observed cytotoxicity of AgNPs in HepG2 and Caco2 cells and that a different mechanism of AgNP-induced mitochondrial injury leads to the cytotoxicity. The HepG2 and Caco2 cells appear to be targets for AgNPs, suggesting that the differences in the mechanisms of toxicity induced by AgNP may be largely a consequence of the type of cells used [93]. Another study reported a correlation between AgNP size and inhibitory effects on mitochondria, with smaller AgNPs of 15 nm significantly more toxic than larger AgNPs of 55 nm [94]. Thus, oxidative stress, cell type, and preparation of AgNPs all play a role in the toxicity. With regard to the environment, a recent study found that AgNPs have a significant impact on the microbial community and severely disrupt the natural seasonal progression of tundra assemblages [95]. This effect was evidenced by levels of differential respiration in 0.066% AgNP-treated soil that were only half that of control soils, a decrease in signature bacterial fatty acids, and changes in both richness and evenness in bacterial and fungal DNA sequence assemblages [95]. Similarly, Völker et al. investigated the effects of AgNPs on Potamopyrgus antipodarum, a freshwater mudsnail, and found that AgNPs decreased their reproduction [96]. Thus, further assessment of the environmental pollution and risks due to AgNP exposure is required to prevent damage to the environment.
5. Applications of AgNPs
AgNPs have been widely used as an antibacterial coat in medical applications such as wound dressings, cardiovascular implants, catheters, orthopedic implants, and dental composites.
5.1. Wound Dressings
Silver wound dressings have been used for over a decade to clinically treat various wounds, such as burns (Table 1), chronic ulcers, toxic epidermal necrolysis, and pemphigus [30]. Surprisingly, compared to standard silver sulfadiazine and gauze dressings, AgNP wound dressings significantly decreased wound healing time by an average of 3.35 days while simultaneously increasing bacterial clearance from infected wounds with no adverse effects [38]. Meanwhile, AgNP wound dressings could enhance healing in superficial burn wounds compared with conventional 1% silver sulfadiazine cream or plain petrolatum gauze [97]. However, AgNP wound dressings made no difference in the healing of deep burn wounds, compared with 1% silver sulfadiazine, suggesting that AgNPs accelerate reepithelialization but not new tissue formation, such as angiogenesis and proliferation [97].
Commonly used burn topical antimicrobials.
Agent
Advantages
Disadvantages
0.5% silver nitrate solutionIntroduced in 1964
(i) Bactericidal against most gram positive, gram negatives, and yeast(ii) Avoids mucopurulent exudate formation (pseudoeschar)(iii) Minimal pain after application(iv) No hypersensitivity
Mafenide acetate—historically 11.1% in water-soluble cream, but newer formulation is 8.5%First introduced in 1964
(i) Bacteriostatic against most gram positives, gram negatives; may be more effective for clostridial and pseudomonal infections than silver nitrate or SSD(ii) Good eschar penetration
(i) Potential loss of bacteriostatic action at high (>106) bacterial loads(ii) Effective concentration in eschar drops below therapeutic levels after 10 hours—needing twice daily application(iii) Metabolic acidosis [drug and metabolite (p-carboxybenzenesulfonamide) inhibit carbonic anhydrase—can worsen ventilation](iv) Pain after application(v) Potential hypersensitivity
1% silver sulfadiazine (SSD) water-soluble creamDeveloped in 1968
(i) Bactericidal against most gram positives and some gram negatives(ii) Minimal pain after application
(i) Less activity against certain gram negatives (Enterobacter and Pseudomonas) and yeast(ii) Poor eschar penetration(iii) Forms pseudoeschar that requires daily washings(iv) NeutropeniaA(v) Potential hypersensitivity to sulfa component(vi) Rare silver toxicity
Mafenide acetate—5% solutionFirst introduced in 1971
(i) Similar to cream(ii) Less pain after application versus cream
(i) Similar to cream(ii) Effective concentration in eschar drops below therapeutic levels after 6–8 hours—needing 3x-4x daily application
ActicoatRayon/polyester core encased in dense polyethylene mesh coated with nanocrystalline silver
(i) Bactericidal against most gram positives, gram negatives, and fungus(ii) Sustained silver release for 3–7 days(iii) Minimizes pain from daily dressings
(i) Poor eschar penetration(ii) Requires maintenance of moist dressings for silver release(iii) Rare silver toxicity
Table information modified and compiled from the following references: [67–71].
ANeutropenia thought to be due to transient depression of granulocyte-macrophage progenitor cells in the marrow [67].
As research in this area continues, new ideas for AgNP wound dressings with the intention of further increasing wound healing and antibacterial efficacy are being investigated. For example, a recent chitosan-AgNP wound dressing demonstrated significantly improved wound healing compared with 1% silver sulfadiazine along with the deposition of less silver, which may lower the occurrence of argyria or skin discoloration [98]. Additionally, chitin-AgNP wound dressings possessed a strong antibacterial potential for wound healing applications [99, 100].
5.2. Cardiovascular Implants
In order to reduce the occurrence of endocarditis, a prosthetic silicone heart valve was the first cardiovascular device coated with silver element [101]. The use of silver was intended to prevent bacterial infection on the silicone valve thereby reducing the inflammation response of the heart. However, clinical trials testing the silver heart valve found that silver causes hypersensitivity, inhibits normal fibroblast function, and leads to paravalvular leakage in patients [101]. Thus, efforts turned towards incorporating AgNPs into medical devices as a potential for providing a safe, nontoxic antibacterial coating. The development of a new nanocomposite with AgNPs and diamond-like carbon as a surface coating for heart valves and stents demonstrated antithrombogenic and antibacterial properties [102]. Additionally, studies have also found that incorporation of nanostructured materials into the backbone of polymers in polymeric heart valves improves biocompatibility, resistance to calcification, and durability [103].
5.3. Catheters
Catheters used in the hospital setting have a high propensity for infection, which can lead to unwanted complications. Thus, AgNPs have been investigated as a method of reducing biofilm growth on catheters. Recently, polyurethane catheters have been modified with a coat of AgNPs to create effective antibacterial catheters [104]. Multiple studies have reported that AgNP-coated catheters can effectively reduce bacteria for up to 72 hours in animal models [105–108]. Furthermore, a follow-up 10-day in vivo study in mice confirmed that the AgNP-coated catheter was nontoxic [104]. Similarly, a clinical pilot study investigating the prevention of catheter-associated ventriculitis (CAV) found no incidence of CAV, and all cerebrospinal fluid cultures were negative in the 19 patients that received a AgNP-coated catheter [109]. On the contrary, in the control group of 20 patients, 5 were positive for CAV [109].
5.4. Dentistry
AgNPs have also been applied to dental instruments and bandages. Akhavan et al. demonstrated that incorporating AgNPs into orthodontic adhesives could increase or maintain the shear bond strength of an orthodontic adhesive while simultaneously increasing its resistance to bacteria [110]. A recent study by Chladek et al. found that incorporating AgNPs into dental composites could reduce the microbial colonization of lining materials, enhancing the antifungal efficiency [111]. Similarly, AgNPs incorporated into endodontic fillings displayed an increased antibacterial effect against Streptococcus milleri, S. aureus, and E. faecalis [112].
5.5. Orthopedic and Orthodontic Implants and Fixations
Implant associated and joint replacement bacterial infections are high at 1.0–4.0% and are one of the most serious complications in orthopedic surgery because they are extremely difficult to treat and result in increased morbidity and significantly worse outcomes [31, 32, 41, 42]. Thus, AgNPs have been incorporated into plain poly(methyl methacrylate) bone cement, used for the secure attachment of joint prostheses hip and knee replacement surgery, as a way to reduce bacterial resistance [31, 41]. Similarly, our lab investigated incorporating AgNPs into PLGA grafts as a potential for implant and fixation material in orthopedic and orthodontic surgery [32, 42]. All studies reported markedly increased antibacterial activity without significant toxicity [31, 32, 41, 42]. Additionally, our results indicated that AgNP/PLGA coating is a practical process that is nontoxic, easy to operate, and free of AgNP aggregation (Figures 1 and 2) [32, 76], suggesting that AgNP/PLGA-coated implants have excellent clinical potential for use in orthopedics and orthodontics.
5.6. Other Applications
AgNPs are also available in many commercial products such as water filters and purification systems, deodorants, soaps, socks, food preservation, and room sprays [34–36, 57, 77], which contributes to the increasing market of AgNPs.
6. Future Outlook
The use of AgNPs is already established for many commercial applications and certain medical applications, such as wound dressings, while many new potential applications are being heavily investigated. AgNPs possess great potential due to their antibacterial, antifungal, antiviral, and anti-inflammatory properties while our recent research has revealed novel osteoinductive properties as well. However, the mechanisms and biological interactions behind these properties are not fully understood. For example, the relationship between the size and shape of AgNPs and their biological properties and toxicity is not clearly revealed and thus requires further investigation as AgNP use continues to increase. Therefore, there is a pressing need to fully elucidate the mechanisms concerning the efficacy and toxicity of AgNPs before widespread medical application can occur.
Conflict of Interests
Kang Ting, Chia Soo, and Zhong Zheng are inventors of silver nanoparticle-related patents filed from UCLA.
Acknowledgments
The authors would like to thank Nadia Barakat from the University of California, Berkeley, for assistance in the preparation of this paper. This research is supported by the National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR000124.
RussellA. D.HugoW. B.7 Antimicrobial activity and action of silver1994351370AtiyehB. S.CostagliolaM.HayekS. N.DiboS. A.Effect of silver on burn wound infection control and healing: review of the literature200733213914810.1016/j.burns.2006.06.0102-s2.0-33846660674Van De VoordeK.NijstenT.SchelfhoutK.MoorkensG.LambertJ.Long term use of silver containing nose-drops resulting in systemic argyria2005601333510.1179/acb.2005.0082-s2.0-20444364154VikH.AndersenK. J.JulshamnK.TodnemK.Neuropathy caused by silver absorption from arthroplasty cement1985184338722-s2.0-0021922805SudmannE.VikH.RaitM.TodnemK.AndersenK.-J.JulshamK.FleslandO.RungbyJ.Systemic and local silver accumulation after total hip replacement using silver-impregnated bone cement1994203-41791842-s2.0-0027988466SunY.MayersB.XiaY.Transformation of silver nanospheres into nanobelts and triangular nanoplates through a thermal process2003356756792-s2.0-014174486610.1021/nl034140tPanáčekA.KvítekL.PrucekR.Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity200611033162481625310.1021/jp063826h2-s2.0-33748537717WilliamsD.The relationship between biomaterials and nanotechnology200829121737173810.1016/j.biomaterials.2008.01.0032-s2.0-39749092385Abou El-NourK. M. M.EftaihaA. A.Al-WarthanA.AmmarR. A. A.Synthesis and applications of silver nanoparticles2010331351402-s2.0-7795558054010.1016/j.arabjc.2010.04.008GeL.LiQ.WangM.OuyangJ.LiX.XingM. M. Q.Nanosilver particles in medical applications: synthesis, performance, and toxicity2014912399240710.2147/IJN.S550152-s2.0-84901391283Sato-BerŕuR.RedónR.Vázquez-OlmosA.SanigerJ. M.Silver nanoparticles synthesized by direct photoreduction of metal salts. Application in surface-enhanced Raman spectroscopy20094043763802-s2.0-6524912797210.1002/jrs.2135VigneshwaranN.NachaneR. P.BalasubramanyaR. H.VaradarajanP. V.A novel one-pot “green” synthesis of stable silver nanoparticles using soluble starch2006341122012201810.1016/j.carres.2006.04.0422-s2.0-33745698326XuG.-N.QiaoX.-L.QiuX.-L.ChenJ.-G.Preparation and characterization of stable monodisperse silver nanoparticles via photoreduction20083201–322222610.1016/j.colsurfa.2008.01.0562-s2.0-43449139110KoraA. J.ManjushaR.ArunachalamJ.Superior bactericidal activity of SDS capped silver nanoparticles: synthesis and characterization20092972104210910.1016/j.msec.2009.04.0102-s2.0-68149174933MandalD.BolanderM. E.MukhopadhyayD.SarkarG.MukherjeeP.The use of microorganisms for the formation of metal nanoparticles and their application20066954854922-s2.0-2924444012310.1007/s00253-005-0179-3SintubinL.de WindtW.DickJ.MastJ.Van Der HaD.VerstraeteW.BoonN.Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles200984474174910.1007/s00253-009-2032-62-s2.0-69949122414BalajiD. S.BasavarajaS.DeshpandeR.MaheshD. B.PrabhakarB. K.VenkataramanA.Extracellular biosynthesis of functionalized silver nanoparticles by strains of Cladosporium cladosporioides fungus200968188922-s2.0-5654910817410.1016/j.colsurfb.2008.09.022SolgiM.Evaluation of plant-mediated Silver nanoparticles synthesis and its application in postharvest physiology of cut Flowers201420327928510.1007/s12298-014-0237-32-s2.0-84901580092ReichaF. M.SarhanA.Abdel-HamidM. I.El-SherbinyI. M.Preparation of silver nanoparticles in the presence of chitosan by electrochemical method20128912362442-s2.0-8486021874010.1016/j.carbpol.2012.03.002ThomasV.YallapuM. M.SreedharB.BajpaiS. K.Fabrication, characterization of chitosan/nanosilver film and its potential antibacterial application200920142129214410.1163/156856209X4101022-s2.0-71749115067ShameliK.AhmadM. B.YunusW. M. Z. W.RustaiyanA.IbrahimN. A.ZargarM.AbdollahiY.Green synthesis of silver/montmorillonite/chitosan bionanocomposites using the UV irradiation method and evaluation of antibacterial activity20105187588710.2147/IJN.S136322-s2.0-79952116320HuangH.YangY.Preparation of silver nanoparticles in inorganic clay suspensions20086814294829532-s2.0-5684912233310.1016/j.compscitech.2007.10.003MighriH.HajlaouiH.AkroutA.NajjaaH.NeffatiM.Antimicrobial and antioxidant activities of Artemisia herba-alba essential oil cultivated in Tunisian arid zone20101333803862-s2.0-7795029939110.1016/j.crci.2009.09.008VilasV.PhilipD.MathewJ.Catalytically and biologically active silver nanoparticles synthesized using essential oil2014132743750Vilchis-NestorA. R.Sánchez-MendietaV.Camacho-LópezM. A.Gómez-EspinosaR. M.Camacho-LópezM. A.Arenas-AlatorreJ. A.Solventless synthesis and optical properties of Au and Ag nanoparticles using Camellia sinensis extract20086217-183103310510.1016/j.matlet.2008.01.1382-s2.0-43149121100CalandraT.CohenJ.The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit20053371538154810.1097/01.CCM.0000168253.91200.832-s2.0-22144444944AmendolaV.MeneghettiM.Laser ablation synthesis in solution and size manipulation of noble metal nanoparticles200911203805382110.1039/b900654k2-s2.0-65649152885TsujiT.WatanabeN.TsujiM.Laser induced morphology change of silver colloids: formation of nano-size wires20032111–418919310.1016/S0169-4332(03)00225-32-s2.0-0037657537TienD.-C.TsengK.-H.LiaoC.-Y.TsungT.-T.Colloidal silver fabrication using the spark discharge system and its antimicrobial effect on Staphylococcus aureus200830894895210.1016/j.medengphy.2007.10.0072-s2.0-53049107541ChaloupkaK.MalamY.SeifalianA. M.Nanosilver as a new generation of nanoproduct in biomedical applications201028115805882-s2.0-7795776655610.1016/j.tibtech.2010.07.006AltV.BechertT.SteinrückeP.WagenerM.SeidelP.DingeldeinE.DomannE.SchnettlerR.An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement20042518438343912-s2.0-164227209610.1016/j.biomaterials.2003.10.078ZhengZ.YinW.ZaraJ. N.LiW.KwakJ.MamidiR.LeeM.SiuR. K.NgoR.WangJ.CarpenterD.ZhangX.WuB.TingK.SooC.The use of BMP-2 coupled—nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects201031359293930010.1016/j.biomaterials.2010.08.0412-s2.0-77957971104ZhangG.LiuY.GaoX.ChenY.Synthesis of silver nanoparticles and antibacterial property of silk fabrics treated by silver nanoparticles201491216ChaudhryQ.ScotterM.BlackburnJ.RossB.BoxallA.CastleL.AitkenR.WatkinsR.Applications and implications of nanotechnologies for the food sector200825324125810.1080/026520307017445382-s2.0-46049121157BennT. M.WesterhoffP.Nanoparticle silver released into water from commercially available sock fabrics200842114133413910.1021/es70327182-s2.0-44449144047ManjumeenaR.DuraibabuD.SudhaJ.KalaichelvanP. T.Biogenic nanosilver incorporated reverse osmosis membrane for antibacterial and antifungal activities against selected pathogenic strains: an enhanced eco-friendly water disinfection approach20144910112511332-s2.0-8490130341610.1080/10934529.2014.897149NadwornyP. L.WangJ.TredgetE. E.BurrellR. E.Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model20084324125110.1016/j.nano.2008.04.0062-s2.0-49649122769HuangY.LiX.LiaoZ.ZhangG.LiuQ.TangJ.PengY.LiuX.LuoQ.A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis200733216116610.1016/j.burns.2006.06.0202-s2.0-33846785144PulitJ.BanachM.SzczygłowskaR.BrykM.Nanosilver against fungi. Silver nanoparticles as an effective biocidal factor20136047957982-s2.0-84893415106LokC.-N.HoC.-M.ChenR.HeQ.-Y.YuW.-Y.SunH.TamP. K.-H.ChiuJ.-F.CheC.-M.Silver nanoparticles: partial oxidation and antibacterial activities200712452753410.1007/s00775-007-0208-z2-s2.0-34247595454van de BeltH.NeutD.SchenkW.van HornJ. R.van der MeiH. C.BusscherH. J.Infection of orthopedic implants and the use of antibiotic-loaded bone cements20017265575712-s2.0-003566172010.1080/000164701317268978LiuY.ZhengZ.ZaraJ. N.The antimicrobial and osteoinductive properties of silver nanoparticle/poly (dl-lactic-co-glycolic acid)-coated stainless steel20123334874587562-s2.0-8486688344810.1016/j.biomaterials.2012.08.010OvingtonL. G.The truth about silver2004509, supplement1s10s2-s2.0-16544387829SilverS.PhungL. T.SilverG.Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds20063376276342-s2.0-3374504239210.1007/s10295-006-0139-7SanpuiP.MurugadossA.PrasadP. V. D.GhoshS. S.ChattopadhyayA.The antibacterial properties of a novel chitosan-Ag-nanoparticle composite2008124214214610.1016/j.ijfoodmicro.2008.03.0042-s2.0-43549092247MoronesJ. R.ElechiguerraJ. L.CamachoA.HoltK.KouriJ. B.RamírezJ. T.YacamanM. J.The bactericidal effect of silver nanoparticles200516102346235310.1088/0957-4484/16/10/0592-s2.0-25444497481ShrivastavaS.BeraT.SinghS. K.SinghG.RamachandraraoP.DashD.Characterization of antiplatelet properties of silver nanoparticles2009361357136410.1021/nn900277t2-s2.0-67651204780MasseA.BrunoA.BosettiM.BiasibettiA.CannasM.GallinaroP.Prevention of pin track infection in external fixation with silver coated pins: clinical and microbiological results2000535600604Martinez-CastanonG. A.Niño-MartínezN.Martínez-GutierrezF.Martínez-MendozaJ. R.RuizF.Synthesis and antibacterial activity of silver nanoparticles with different sizes2008108134313482-s2.0-4874911266810.1007/s11051-008-9428-6SotiriouG. A.PratsinisS. E.Antibacterial activity of nanosilver ions and particles201044145649565410.1021/es101072s2-s2.0-77954607451ChoiO.DengK. K.KimN.-J.RossL.Jr.SurampalliR. Y.HuZ.The inhibitory effects of silver nanoparticles, silver ions, and silver chloride colloids on microbial growth200842123066307410.1016/j.watres.2008.02.0212-s2.0-44749089357LokC.-N.HoC.-M.ChenR.HeQ.-Y.YuW.-Y.SunH.TamP. K.-H.ChiuJ.-F.CheC.-M.Proteomic analysis of the mode of antibacterial action of silver nanoparticles20065491692410.1021/pr05040792-s2.0-33645764133KimJ. S.KukE.YuK. N.KimJ.-H.ParkS. J.LeeH. J.KimS. H.ParkY. K.ParkY. H.HwangC.-Y.KimY.-K.LeeY.-S.JeongD. H.ChoM.-H.Antimicrobial effects of silver nanoparticles2007319510110.1016/j.nano.2006.12.0012-s2.0-33947278926LeeW.KimK. J.LeeD. G.A novel mechanism for the antibacterial effect of silver nanoparticles on Escherichia coli20142761191120110.1007/s10534-014-9782-zYamanakaM.HaraK.KudoJ.Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis200571117589759310.1128/AEM.71.11.7589-7593.20052-s2.0-32044447430WooK. J.HyeC. K.KiW. K.ShinS.SoH. K.YongH. P.Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli20087472171217810.1128/AEM.02001-072-s2.0-42049088267YangW.ShenC.JiQ.AnH.WangJ.LiuQ.ZhangZ.Food storage material silver nanoparticles interfere with DNA replication fidelity and bind with DNA20092080851022-s2.0-6524908734610.1088/0957-4484/20/8/085102JeongS. H.YeoS. Y.YiS. C.The effect of filler particle size on the antibacterial properties of compounded polymer/silver fibers20054020540754112-s2.0-2644445064010.1007/s10853-005-4339-8Martinez-CastanonG. A.Niño-MartínezN.Martínez-GutierrezF.Martínez-MendozaJ. R.RuizF.Synthesis and antibacterial activity of silver nanoparticles with different sizes20081081343134810.1007/s11051-008-9428-62-s2.0-48749112668Martinez-GutierrezF.OliveP. L.BanuelosA.OrrantiaE.NinoN.SanchezE. M.RuizF.BachH.Av-GayY.Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles20106568168810.1016/j.nano.2010.02.0012-s2.0-77955591988SadeghiB.GarmaroudiF. S.HashemiM.NezhadH. R.NasrollahiA.ArdalanS.Comparison of the anti-bacterial activity on the nanosilver shapes: nanoparticles, nanorods and nanoplates201223122262-s2.0-8485610910010.1016/j.apt.2010.11.011GaikwadS.IngleA.GadeA.RaiM.FalangaA.IncoronatoN.RussoL.GaldieroS.GaldieroM.Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3201384303431410.2147/IJN.S500702-s2.0-84887334090Baram-PintoD.ShuklaS.PerkasN.GedankenA.SaridR.Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate20092081497150210.1021/bc900215b2-s2.0-70349154653LuL.SunR. W.-Y.ChenR.Silver nanoparticles inhibit hepatitis B virus replication20081322532622-s2.0-42149148881LaraH. H.Ayala-NuñezN. V.Ixtepan-TurrentL.Rodriguez-PadillaC.Mode of antiviral action of silver nanoparticles against HIV-120108, article 110.1186/1477-3155-8-12-s2.0-76749144670HuR. L.LiS. R.KongF. J.HouR. J.GuanX. L.GuoF.Inhibition effect of silver nanoparticles on herpes simplex virus 2201413370227028D'AvignonL. C.SaffleJ. R.ChungK. K.CancioL. C.Prevention and management of infections associated with burns in the combat casualty2008643S277S28610.1097/TA.0b013e318163c3e42-s2.0-43149084614TredgetE. E.ShankowskyH. A.RennieR.BurrellR. E.LogsettyS.Pseudomonas infections in the thermally injured patient200430132610.1016/j.burns.2003.08.0072-s2.0-0346338090MartineauL.DavisS. C.PengH. T.HungA.Controlling methicillin resistant Staphyloccocus aureus and pseudomonas aeruginosa wound infections with a novel biomaterial200720421722710.1080/107175407014812752-s2.0-34548206469BarilloD. J.Topical antimicrobials in burn wound care: a recent history20082071921982-s2.0-49449110017CioffiW. G.Conventional warfare: ballistic, blast, and burn injuries1989349377MackayC. R.Moving targets: cell migration inhibitors as new anti-inflammatory therapies20089998899810.1038/ni.f.2102-s2.0-50049089619ShinS.-H.YeM.-K.The effect of nano-silver on allergic rhinitis model in mice2012542222272-s2.0-8487003302110.3342/ceo.2012.5.4.222WongK. K. Y.CheungS. O. F.HuangL.NiuJ.TaoC.HoC.-M.CheC.-M.TamP. K. H.Further evidence of the anti-inflammatory effects of silver nanoparticles200947112911352-s2.0-6774914223310.1002/cmdc.200900049ZhangS.LiuX.WangH.PengJ.WongK. K. Y.Silver nanoparticle-coated suture effectively reduces inflammation and improves mechanical strength at intestinal anastomosis in mice2014494606613LiuY.ZhengZ.ZaraJ. N.The antimicrobial and osteoinductive properties of silver nanoparticle/poly (DL-lactic-co-glycolic acid)-coated stainless steel201233348745875610.1016/j.biomaterials.2012.08.0102-s2.0-84866883448ChenX.SchluesenerH. J.Nanosilver: a nanoproduct in medical application2008176111210.1016/j.toxlet.2007.10.0042-s2.0-37049000154KimY. S.KimJ. S.ChoH. S.RhaD. S.KimJ. M.ParkJ. D.ChoiB. S.LimR.ChangH. K.ChungY. H.KwonI. H.JeongJ.HanB. S.YuI. J.Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats200820657558310.1080/089583707018746632-s2.0-42649143562JiJ. H.JungJ. H.KimS. S.YoonJ.-U.ParkJ. D.ChoiB. S.ChungY. H.KwonI. H.JeongJ.HanB. S.ShinJ. H.SungJ. H.SongK. S.YuI. J.Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats200719108578712-s2.0-3454776437410.1080/08958370701432108ManeewattanapinyoP.BanlunaraW.ThammacharoenC.EkgasitS.KaewamatawongT.An evaluation of acute toxicity of colloidal silver nanoparticles201173111417142310.1292/jvms.11-00382-s2.0-82955242445SungJ. H.JiJ. H.ParkJ. D.YoonJ. U.KimD. S.JeonK. S.SongM. Y.JeongJ.HanB. S.HanJ. H.ChungY. H.ChangH. K.LeeJ. H.ChoM. H.KelmanB. J.YuI. J.Subchronic inhalation toxicity of silver nanoparticles2009108245246110.1093/toxsci/kfn2462-s2.0-64349090027TangJ.XiongL.WangS.WangJ.LiuL.LiJ.WanZ.XiT.Influence of silver nanoparticles on neurons and blood-brain barrier via subcutaneous injection in rats2008255250250410.1016/j.apsusc.2008.06.0582-s2.0-54849440522VandebrielR. J.TonkE. C. M.de la Fonteyne-BlankestijnL. J.GremmerE. R.VerharenH. W.van der VenL. T.van LoverenH.de JongW. H.Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats201411, article 2110.1186/1743-8977-11-212-s2.0-84899770393de JongW. H.van der venL. T. M.SleijffersA.ParkM. V. D. Z.JansenE. H. J. M.van LoverenH.VandebrielR. J.Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats201334338333834310.1016/j.biomaterials.2013.06.0482-s2.0-84881663479LeeK. J.NallathambyP. D.BrowningL. M.OsgoodC. J.Nancy XuX.-H.In vivo imaging of transport and biocompatibility of single silver nanoparticles in early development of zebrafish embryos20071213314310.1021/nn700048y2-s2.0-42549154982AshaRaniP. V.MunG. L. K.HandeM. P.ValiyaveettilS.Cytotoxicity and genotoxicity of silver nanoparticles in human cells20093227929010.1021/nn800596w2-s2.0-63449105617ShinS.-H.YeM.-K.KimH.-S.KangH.-S.The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells20077131813181810.1016/j.intimp.2007.08.0252-s2.0-35748933519HussainS. M.JavorinaA. K.SchrandA. M.DuhartH. M. H. M.AliS. F.SchlagerJ. J.The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion200692245646310.1093/toxsci/kfl0202-s2.0-33745775422HussainS. M.HessK. L.GearhartJ. M.GeissK. T.SchlagerJ. J.In vitro toxicity of nanoparticles in BRL 3A rat liver cells200519797598310.1016/j.tiv.2005.06.0342-s2.0-27644541020HsinY. H.ChenC. F.HuangS.ShihT. S.LaiP. S.ChuehP. J.The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells20081793130139ParkS.LeeY. K.JungM.KimK. H.ChungN.AhnE.-K.LimY.LeeK.-H.Cellular toxicity of various inhalable metal nanoparticles on human alveolar epithelial cells2007191596510.1080/089583707014932822-s2.0-34548832559McShanD.RayP. C.YuH.Molecular toxicity mechanism of nanosilver201422111612710.1016/j.jfda.2014.01.0102-s2.0-84901604308SahuS. C.ZhengJ.GrahamL.ChenL.IhrieJ.YourickJ. J.SprandoR. L.Comparative cytotoxicity of nanosilver in human liver HepG2 and colon Caco2 cells in culture201434111155116610.1002/jat.29942-s2.0-84893666757CarlsonC.HusseinS. M.SchrandA. M.Braydich-StolleL. K.HessK. L.JonesR. L.SchlagerJ. J.Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species200811243136081361910.1021/jp712087m2-s2.0-55949113520KumarN.PalmerG. R.ShahV.WalkerV. K.The effect of silver nanoparticles on seasonal change in arctic tundra bacterial and fungal assemblages201496e9995310.1371/journal.pone.0099953VölkerC.GräfT.SchneiderI.OetkenM.OehlmannJ.Combined effects of silver nanoparticles and 17α-ethinylestradiol on the freshwater mudsnail Potamopyrgus antipodarum20142118106611067010.1007/s11356-014-3067-52-s2.0-84901581499ChenJ.HanC.-M.LinX.-W.TangZ.-J.SuS.-J.Effect of silver nanoparticle dressing on second degree burn wound200644150522-s2.0-33746866368LuS.GaoW.GuH. Y.Construction, application and biosafety of silver nanocrystalline chitosan wound dressing200834562362810.1016/j.burns.2007.08.0202-s2.0-44649203035SinghR.SinghD.Chitin membranes containing silver nanoparticles for wound dressing application201411326426810.1111/j.1742-481X.2012.01084.x2-s2.0-84900418826MadhumathiK.KumarP. T. S.AbhilashS.Development of novel chitin/nanosilver composite scaffolds for wound dressing applications201021280781310.1007/s10856-009-3877-z2-s2.0-77951258922GrunkemeierG. L.JinR.StarrA.Prosthetic heart valves: objective performance criteria versus randomized clinical trial20068237767802-s2.0-3374736204810.1016/j.athoracsur.2006.06.037AndaraM.AgarwalA.ScholvinD.GerhardtR. A.DoraiswamyA.JinC.NarayanR. J.ShihC.-C.ShihC.-M.LinS.-J.SuY.-Y.Hemocompatibility of diamondlike carbon-metal composite thin films20061511-121941194810.1016/j.diamond.2006.05.0132-s2.0-33751163493GhanbariH.ViatgeH.KidaneA. G.BurriesciG.TavakoliM.SeifalianA. M.Polymeric heart valves: new materials, emerging hopes200927635936710.1016/j.tibtech.2009.03.0022-s2.0-65549103981RoeD.KarandikarB.Bonn-SavageN.GibbinsB.RoulletJ.-B.Antimicrobial surface functionalization of plastic catheters by silver nanoparticles200861486987610.1093/jac/dkn0342-s2.0-41149149262HsuS.-H.TsengH.-J.LinY.-C.The biocompatibility and antibacterial properties of waterborne polyurethane-silver nanocomposites20103126679668082-s2.0-7795438747510.1016/j.biomaterials.2010.05.015de MelA.ChaloupkaK.MalamY.DarbyshireA.CousinsB.SeifalianA. M.A silver nanocomposite biomaterial for blood-contacting implants201210092348235710.1002/jbm.a.341772-s2.0-84864403470PaladiniF.PolliniM.DepontiD.di GiancamilloA.PerettiG.SanninoA.Effect of silver nanocoatings on catheters for haemodialysis in terms of cell viability, proliferation, morphology and antibacterial activity20132441105111210.1007/s10856-013-4870-02-s2.0-84876283160ChouC.-W.HsuS.-H.WangP.-H.Biostability and biocompatibility of poly(ether)urethane containing gold or silver nanoparticles in a porcine model200884378579410.1002/jbm.a.313872-s2.0-39049141585LacknerP.BeerR.BroessnerG.HelbokR.GalianoK.PleiferC.PfauslerB.BrenneisC.HuckC.EngelhardtK.ObwegeserA. A.SchmutzhardE.Efficacy of silver nanoparticles-impregnated external ventricular drain catheters in patients with acute occlusive hydrocephalus20088336036510.1007/s12028-008-9071-12-s2.0-51449102583AkhavanA.SodagarA.MojtahedzadehF.SodagarK.Investigating the effect of incorporating nanosilver/nanohydroxyapatite particles on the shear bond strength of orthodontic adhesives20137151038104210.3109/00016357.2012.7416992-s2.0-84883570190ChladekG.KasperskiJ.Barszczewska-RybarekI.ZmudzkiJ.Sorption, solubility, bond strength and hardness of denture soft lining incorporated with silver nanoparticles20131415635742-s2.0-8487218961810.3390/ijms14010563MagalhãesA. P. R.SantosL. B.LopesL. G.Nanosilver application in dental cements20122012636543810.5402/2012/365438